West Pharmaceutical to Announce Q4 Earnings on February 12
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy WST?
Source: seekingalpha
- Earnings Announcement: West Pharmaceutical (WST) is set to release its Q4 earnings on February 12 before market open, with consensus EPS estimate at $1.83, reflecting a 0.5% year-over-year increase, which could influence stock performance.
- Revenue Expectations: The anticipated revenue for Q4 is $794.8 million, representing a 6.1% year-over-year growth, and achieving this would further solidify the company's market position in the pharmaceutical sector.
- Performance Beat Record: Over the past two years, WST has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, showcasing its strong profitability and market adaptability.
- Revision Trends: In the last three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates experienced no upward revisions and two downward adjustments, indicating a cautious market outlook on the company's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 243.610
Low
285.00
Averages
348.70
High
375.00
Current: 243.610
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
WEST PHARMACEUTICAL SERVICES INC: UBS LOWERS TARGET PRICE FROM $355 TO $340
Company Overview: West Pharmaceutical Services, Inc. is a leading provider of pharmaceutical packaging and delivery solutions.
Stock Price Adjustment: The company has cut its target stock price from $355 to $340.
See More
West Pharmaceutical Services Reports Strong Q4 2025 Earnings and Positive Outlook
- Significant Revenue Growth: West Pharmaceutical achieved $805 million in revenue for Q4 2025, reflecting a 7.5% increase year-over-year, with organic growth at 3.3%, indicating strong demand and enhanced market position in the biopharmaceutical sector.
- Improved Profitability: The adjusted earnings per share (EPS) reached $2.04, up 12% from the previous year, while gross margin stood at 37.8%, a 130 basis point increase, showcasing the company's success in cost control and product value enhancement.
- Optimistic Future Outlook: Management guided for 2026 revenue between $3.215 billion and $3.275 billion, with organic growth projected at 5% to 7%, emphasizing that HVP components will be the primary growth driver, reflecting confidence in future market conditions.
- Strong Cash Flow: Free cash flow for 2025 reached $469 million, a 70% year-over-year increase, providing a solid foundation for future investments and shareholder returns, indicating robust financial health.
See More
West Pharma (WST) Q4 2025 Earnings Call Transcript
See More
WEST PHARMACEUTICAL SERVICES STOCK RISES 2.8% FOLLOWING POSITIVE 2026 PROFIT OUTLOOK
Stock Performance: West Pharmaceutical Services shares increased by 2.8%.
Profit Forecast: The company provided an upbeat profit forecast for 2026.
See More
West Pharma Executive Reports Steady Customer Behavior and Calls Annual Forecast a Conservative Beginning - Conference Call
Customer Behavior Insights: West Pharma executives report no significant changes in customer behavior, indicating stability in their market interactions.
Annual Forecast Overview: The company describes its annual forecast as conservative, reflecting a cautious approach to future business expectations.
See More
West Pharma Executive Anticipates GLP-1 Demand Growth in 2026, but Slower than 2025 - Conference Call Insights
- Growth Expectations: West Pharma executives anticipate that demand for GLP-1 medications will grow in 2026, albeit at a slower pace than in 2025.
- Market Trends: The company is observing trends in the pharmaceutical market that may influence the production and demand for these medications.
See More
WEST PHARMACEUTICAL SERVICES INC: UBS LOWERS TARGET PRICE FROM $355 TO $340
Company Overview: West Pharmaceutical Services, Inc. is a leading provider of pharmaceutical packaging and delivery solutions.
Stock Price Adjustment: The company has cut its target stock price from $355 to $340.
See More
West Pharmaceutical Services Reports Strong Q4 2025 Earnings and Positive Outlook
- Significant Revenue Growth: West Pharmaceutical achieved $805 million in revenue for Q4 2025, reflecting a 7.5% increase year-over-year, with organic growth at 3.3%, indicating strong demand and enhanced market position in the biopharmaceutical sector.
- Improved Profitability: The adjusted earnings per share (EPS) reached $2.04, up 12% from the previous year, while gross margin stood at 37.8%, a 130 basis point increase, showcasing the company's success in cost control and product value enhancement.
- Optimistic Future Outlook: Management guided for 2026 revenue between $3.215 billion and $3.275 billion, with organic growth projected at 5% to 7%, emphasizing that HVP components will be the primary growth driver, reflecting confidence in future market conditions.
- Strong Cash Flow: Free cash flow for 2025 reached $469 million, a 70% year-over-year increase, providing a solid foundation for future investments and shareholder returns, indicating robust financial health.
See More
West Pharma (WST) Q4 2025 Earnings Call Transcript
See More
WEST PHARMACEUTICAL SERVICES STOCK RISES 2.8% FOLLOWING POSITIVE 2026 PROFIT OUTLOOK
Stock Performance: West Pharmaceutical Services shares increased by 2.8%.
Profit Forecast: The company provided an upbeat profit forecast for 2026.
See More
West Pharma Executive Reports Steady Customer Behavior and Calls Annual Forecast a Conservative Beginning - Conference Call
Customer Behavior Insights: West Pharma executives report no significant changes in customer behavior, indicating stability in their market interactions.
Annual Forecast Overview: The company describes its annual forecast as conservative, reflecting a cautious approach to future business expectations.
See More
West Pharma Executive Anticipates GLP-1 Demand Growth in 2026, but Slower than 2025 - Conference Call Insights
- Growth Expectations: West Pharma executives anticipate that demand for GLP-1 medications will grow in 2026, albeit at a slower pace than in 2025.
- Market Trends: The company is observing trends in the pharmaceutical market that may influence the production and demand for these medications.
See More
